Clinical Trial

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

Study acronym: SEACLIFF
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to assess the safety and tolerability of AZD0516 as monotherapy and/or in combination with other anti-cancer agents for treatment of metastatic prostate cancer.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2025-09-12; most recent amendment 2026-07-14.
Status change: Not Yet Recruiting → Recruiting 2025-10-14
Trial Details
NCT Number NCT07181161
Lead Sponsor AstraZeneca
Collaborators: Parexel
Conditions Metastatic Prostate Cancer
Enrollment 177 participants
Start Date 2025-10-01
Primary Completion 2029-01-18 (estimated)
Study Completion 2029-01-18 (estimated)
Updated on ClinicalTrials.gov 2026-07-15